{{Rsnum
|rsid=6851702
|Chromosome=4
|position=27054735
|Orientation=plus
|GMAF=0.1924
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 99.1 | 0.9 | 0.0
| HCB | 35.0 | 50.4 | 14.6
| JPT | 31.0 | 55.8 | 13.3
| YRI | 63.9 | 30.6 | 5.4
| ASW | 63.2 | 35.1 | 1.8
| CHB | 35.0 | 50.4 | 14.6
| CHD | 30.3 | 51.4 | 18.3
| GIH | 93.1 | 6.9 | 0.0
| LWK | 62.7 | 34.5 | 2.7
| MEX | 69.0 | 27.6 | 3.4
| MKK | 57.1 | 37.8 | 5.1
| TSI | 89.2 | 8.8 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6851702
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.07, combined P value= 3.35E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470233
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6851702
|overall_frequency_n=23
|overall_frequency_d=128
|overall_frequency=0.179688
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=22
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}